Literature DB >> 26486104

PDZRN4 acts as a suppressor of cell proliferation in human liver cancer cell lines.

Taotao Hu1,2, Hong Yang1,3, Ze-Guang Han1,4,2.   

Abstract

Recently, some reports show that Ligand of Numb Protein-X 1 (LNX1) could be a suppressor gene in gliomas, while our current research has firstly shown that PDZ domain containing ring finger 4 (PDZRN4), another member of LNX family, could also be a potential suppressor in hepatocellular carcinoma (HCC). PDZRN4, also named LNX4 (Ligand of Numb Protein-X 4), is a member of the LNX family. We recently found that PDZRN4, but not LNX1, was down-regulated in HCC samples, and the role of PDZRN4 in the progression of HCC had not been studied before. To address this question, firstly, we evaluated the expression of PDZRN4 in HCC samples and adjacent non-cancerous tissues. Semi-quantitative polymerase chain reaction showed that PDZRN4 was down-regulated in 24/36 (66.7%) HCC samples separately. In addition, our research shows that PDZRN4 is silenced in all of the 12 HCC cell lines tested. Subsequently, cell-based functional assay exhibited that ectopic expression of PDZRN4 inhibits the proliferation, plate colony formation and anchorage-independent colony formation of HCC cells. Collectively, our results showed that PDZRN4 might be a potential tumour suppressor gene and had anti-proliferative effect on HCC cell proliferation, which would be of great significance to the researches on HCC.
Copyright © 2015 John Wiley & Sons, Ltd.

Entities:  

Keywords:  HCC; LNX; PDZRN4; overexpression; proliferation

Mesh:

Substances:

Year:  2015        PMID: 26486104     DOI: 10.1002/cbf.3130

Source DB:  PubMed          Journal:  Cell Biochem Funct        ISSN: 0263-6484            Impact factor:   3.685


  6 in total

1.  A general calculus of fitness landscapes finds genes under selection in cancers.

Authors:  Teng-Kuei Hsu; Jennifer Asmussen; Amanda Koire; Byung-Kwon Choi; Mayur A Gadhikar; Eunna Huh; Chih-Hsu Lin; Daniel M Konecki; Young Won Kim; Curtis R Pickering; Marek Kimmel; Lawrence A Donehower; Mitchell J Frederick; Jeffrey N Myers; Panagiotis Katsonis; Olivier Lichtarge
Journal:  Genome Res       Date:  2022-03-17       Impact factor: 9.438

2.  Abnormal expression of mRNA, microRNA alteration and aberrant DNA methylation patterns in rectal adenocarcinoma.

Authors:  Yang Hua; Xiukun Ma; Xianglong Liu; Xiangfei Yuan; Hai Qin; Xipeng Zhang
Journal:  PLoS One       Date:  2017-03-28       Impact factor: 3.240

3.  Genomic signatures reveal DNA damage response deficiency in colorectal cancer brain metastases.

Authors:  Jing Sun; Cheng Wang; Yi Zhang; Lingyan Xu; Weijia Fang; Yuping Zhu; Yi Zheng; Xiaofeng Chen; Xiju Xie; Xinhua Hu; Weidong Hu; Jingyu Zheng; Ping Li; Jian Yu; Zhu Mei; Xiaomin Cai; Biao Wang; Zhibin Hu; Yongqian Shu; Hongbing Shen; Yanhong Gu
Journal:  Nat Commun       Date:  2019-07-18       Impact factor: 14.919

4.  PDZRN4 suppresses tumorigenesis and androgen therapy-resistance in prostate cancer.

Authors:  Peng Jin; Lielin Wu; Gang Zhang; Bo Yang; Bisong Zhu
Journal:  J Cancer       Date:  2022-04-18       Impact factor: 4.207

5.  Suppression of cancer stemness by upregulating Ligand-of-Numb protein X1 in colorectal carcinoma.

Authors:  Lin Ma; Lan Wang; Yating Shan; Muhammad Nafees; Elshoura Ihab; Ruhui Zhang; Fangjun Wang; Wu Yin
Journal:  PLoS One       Date:  2017-11-30       Impact factor: 3.240

6.  PDZRN4-mediated colon cancer cell proliferation and dissemination is regulated by miR-221-3p.

Authors:  Xiaojian Liu; Chungen Xing
Journal:  Transl Cancer Res       Date:  2019-08       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.